TB-500 (Thymosin Beta-4) Australia 2026: Research Guide, Dosing & Where to Buy

TB-500 is the research-grade synthetic analogue of Thymosin Beta-4 (Tβ4), a naturally occurring 43-amino-acid protein encoded by the TMSB4X gene and found in virtually all human and animal cells. The primary driver of its biological activity is the actin-binding domain (residues 17–23, the LKKTETQ sequence), which regulates G-actin/F-actin dynamics central to cell migration and tissue repair.

Thymosin Beta-4 was first isolated from thymus tissue in the 1960s. It is one of the most abundant intracellular peptides in mammalian cells, with particularly high concentrations in platelets, wound fluid, and motile cells. Plasma Tβ4 levels increase significantly following injury, suggesting an endogenous role as a tissue damage signal that recruits repair processes.

Did You Know? Thymosin Beta-4 is one of the most abundant intracellular proteins in mammalian cells (present at concentrations of 0.5–0.8 mM in many cell types. Its concentration in platelets is exceptionally high (~0.5 mg/mL), and it is released at wound sites during platelet activation) positioning it as one of the first regenerative signals arriving at an injury site.

TB-500's primary mechanism involves sequestration of G-actin (globular actin monomers) through its LKKTETQ domain. Actin dynamics, the cycling between G-actin and F-actin (filamentous actin), are central to cell motility, shape change, and migration. By modulating this balance, TB-500 promotes:

• Cell migration, upregulation of keratinocyte, endothelial, and progenitor cell migration to sites of injury; this is a systemic effect, allowing TB-500 to recruit repair cells from distant sites
• Angiogenesis, promotion of new blood vessel formation via endothelial cell migration and tube formation; critical for oxygenating healing tissue
• MMP upregulation, matrix metalloproteinase activity supports extracellular matrix remodelling during repair
• Anti-apoptotic effects, TB-500 reduces programmed cell death in cardiac and neural tissue under ischaemic conditions via ILK (integrin-linked kinase) signalling
• Anti-inflammatory signalling, TB-500 downregulates pro-inflammatory cytokines including TNF-α and IL-1β via TLR4/MyD88 pathway modulation

Key Mechanism: Systemic Cell Recruitment Unlike most repair peptides that work locally, TB-500's actin-mediated cell migration mechanism is systemic. Subcutaneously injected TB-500 can recruit progenitor cells and endothelial cells from distant sites (bone marrow, circulation) to an injury site, making it effective for tissue repair even when not injected locally at the wound.

Thymosin Beta-4 / TB-500 has been studied across a wide range of tissue types and injury models. The research base spans decades of preclinical work and early-phase human data (for corneal applications):

The corneal application represents the most clinically advanced data for the Tβ4 compound class, RegeneRx Biopharmaceuticals conducted Phase 2 trials of RGN-259 (topical Tβ4) showing statistically significant improvements in corneal healing endpoints. This clinical programme provides important translational support for the broader TB-500 research base.

TB-500 and BPC-157 are the two most commonly co-studied tissue repair peptides. Their mechanisms are complementary rather than redundant, they address different phases and aspects of the repair process:

Research combining both peptides has demonstrated synergistic outcomes in soft tissue repair models, the combination addresses both local repair signalling (BPC-157) and systemic cell recruitment and migration (TB-500). OzPeps stocks a pre-combined BPC-157 / TB-500 blend for researchers studying both pathways simultaneously. See also: BPC-157 + TB-500 stack research guide →

TB-500 dosing across published preclinical research and documented research protocols. These are not clinical recommendations:

Loading and Maintenance Pattern A common pattern in TB-500 research protocols is a higher-frequency "loading" phase (twice weekly for 2–4 weeks) followed by a reduced-frequency "maintenance" phase (weekly or biweekly). This mirrors similar titration approaches used with other peptides and allows initial tissue saturation before stepping down to a maintenance dose.

Based on preclinical data and documented research protocol reports, TB-500 produces time-dependent effects across tissue repair endpoints:

Onset speed varies significantly by tissue type. Wound healing endpoints (epithelialisation, wound area reduction) show measurable changes within the first 1–2 weeks. Tendon repair improvements are typically measured at 4–6 weeks. Cardiac functional preservation endpoints in preclinical models are assessed at 2–4 weeks post-MI administration.

TB-500's adverse event profile in preclinical research is generally mild. The compound has been studied across multiple species and injury models without significant toxicity signals at research doses:

No organ toxicity, mutagenicity, or carcinogenicity signals have been reported in published TB-500 / Tβ4 research. The corneal Tβ4 Phase 2 trials (RGN-259) reported no serious adverse events and good local tolerability. The absence of receptor-mediated side effects (no known receptor target other than G-actin sequestration) is a distinguishing feature of TB-500's tolerability profile.

Research-grade TB-500 is supplied as a lyophilised powder. Common vial sizes are 5mg and 10mg. Reconstitute and store research-grade vials following the standard protocol, see our peptide reconstitution & storage guide.

Compound-specific notes: TB-500 requires more care than shorter peptides due to its 43-amino-acid chain, swirl gently and, if dissolution is slow, warm the vial in the hand (not heat). A 5mg vial with 1mL bacteriostatic water = 5mg/mL; a 10mg vial with 2mL = 5mg/mL. Lyophilised TB-500 is stable at −20°C for 24+ months; the reconstituted solution should be stored at 2–8°C.

Use OzPeps' free reconstitution calculator for any vial size or target dose.

What is TB-500 used for in research?

TB-500 is primarily studied for tissue repair and regeneration, including wound healing, tendon and ligament repair, cardiac protection post-injury, neurological recovery, and anti-inflammatory activity. Its systemic cell migration mechanism makes it particularly useful in models where repair cells need to be recruited to an injury site from a distance.

Is TB-500 the same as Thymosin Beta-4?

TB-500 is a synthetic research analogue of Thymosin Beta-4 (Tβ4). In the research peptide market, "TB-500" typically refers to the full 43-amino-acid Tβ4 sequence. The primary biological activity comes from the LKKTETQ actin-binding domain (residues 17–23). The terms are often used interchangeably in research contexts.

Is TB-500 available in Australia?

Research-grade TB-500 is available from Australian suppliers for laboratory research. OzPeps stocks TB-500 individually and as a pre-combined blend with BPC-157. TB-500 is not TGA-approved as a therapeutic medicine in Australia.

What is the difference between TB-500 and BPC-157?

TB-500 works primarily through actin sequestration to promote systemic cell migration and angiogenesis, recruiting repair cells from distant sites. BPC-157 works through VEGFR2 and NO-signalling pathways with primarily local effects at the administration site. Their mechanisms are complementary: BPC-157 addresses local repair signalling; TB-500 addresses systemic cell recruitment. Many research protocols combine both. See: BPC-157 + TB-500 stack guide →

How do you reconstitute TB-500?

Follow the standard peptide reconstitution & storage protocol. Compound-specific note: TB-500's 43-amino-acid chain can be slower to dissolve than shorter peptides, gentle palm warming (not heat) aids dissolution. A 10mg vial with 2mL bacteriostatic water = 5mg/mL. Use the OzPeps reconstitution calculator for precise volumes.

What dose of TB-500 is used in research?

Research protocols typically use a loading phase of 4–10 mg twice weekly for 2–4 weeks, followed by a maintenance phase of 2–5 mg once weekly or biweekly. Cardiac preclinical models use weight-adjusted doses (~150–300 mcg/kg). Specific doses vary by research application, tissue type, and model species.

Does TB-500 have any side effects?

Published preclinical research and the Tβ4 corneal Phase 2 trials (RGN-259) have not identified significant organ toxicity or serious adverse events at research doses. The most practically reported issues are injection site discomfort and dissolution difficulty (the long chain requires care in reconstitution). No receptor-mediated side effects are documented given TB-500's mechanism (actin sequestration rather than receptor agonism).

OzPeps supplies research-grade TB-500 Australia-wide with Certificate of Analysis documentation, fast dispatch, and Express Post shipping. Available individually and as a pre-combined blend with BPC-157.

TB-500 10mg → · BPC-157 / TB-500 Blend →

Related guides: BPC-157 + TB-500 stack research guide → · BPC-157 research guide →

All TB-500 products sold by OzPeps are supplied strictly for laboratory and in-vitro research purposes. They are not TGA-approved therapeutic goods, are not intended for human or animal consumption, and are not sold for diagnostic or treatment purposes. Researchers are responsible for compliance with all applicable regulations.